ReviewEndocrine reviews2025
Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.
Review in Endocrine reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Delayed Hypothalamic Dysfunction Presenting as Recurrent Hypothermia After Treatment of Suprasellar Germinoma: A Case Report.Clinical case reports · 2026Article
- IMPROVE 2025: The 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence.Clinical obesity · 2026Article
- Approach to the patient with acquired hypothalamic syndrome.The Journal of clinical endocrinology and metabolism · 2026Review
- Hypothalamic syndrome and acquired hypothalamic obesity: from fragmented care to integrated multidisciplinary management.Pituitary · 2026Review
- Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review.Current obesity reports · 2026Review
- Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.Journal of clinical research in pediatric endocrinology · 2026Review
- Review
- Hyperphagia in craniopharyngioma- a real-world study from the international hypothalamic-pituitary brain tumors patient registry.Scientific reports · 2026Article
- Treatment Priorities in Craniopharyngioma: Perspectives of Survivors and Caregivers.Biomedicines · 2026Article
- Expert meeting report: epidemiology and management of acquired hypothalamic obesity.Frontiers in endocrinology · 2026Review
- Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.Frontiers in endocrinology · 2026Review
- Hunger, satiety, and eating behavior after craniopharyngioma - narrative review on current management and future therapeutic perspectives.Frontiers in endocrinology · 2026Review
- Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity followingFrontiers in endocrinology · 2026Article
- Sleep Disorders, Dysregulation of Circadian Rhythms, and Fatigue After Craniopharyngioma-A Narrative Review.Biomedicines · 2025Review
- Unlocking the heterogeneity of pediatric obesity: a phenotypic subtype-based paradigm for precision management.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The hypothalamus is the key regulator of human energy balance. Hypothalamic dysfunction leads to (morbid) hypothalamic obesity, but may have many more consequences such as hypopituitarism, adipsia, disruption of the circadian rhythm, decreased energy expenditure, low core body temperature, and behavioral changes. Many patients with hypothalamic dysfunction experience chronic fatigue, increased daytime sleepiness, headaches, inactivity, and mood disorders, all of which may contribute to the development of obesity. Adipsic arginine vasopressin deficiency, severe hypothermia, uncontrollable hyperphagia, and severe mood disorders may require 24/7 management. Signs and symptoms may be severe or mild. Severe hypothalamic dysfunction is usually readily diagnosed, but less severe hypothalamic dysfunction is much harder to recognize because, among other things, of its multifaceted presentation. Through raising awareness and by better categorization of the different clinical signs and symptoms of hypothalamic dysfunction within different domains, the underlying cause for fatigue and obesity observed in patients with hypothalamic dysfunction may be better understood, which in turn, will open new perspectives on successful management options. In this review, the state of the art for diagnostics and management of acquired hypothalamic dysfunction is summarized and a new management algorithm is suggested. The lessons learned from pediatric patients with acquired hypothalamic dysfunction, including hypothalamic obesity management through the different clinical domains, may also prove to be useful for patients with congenital or genetic forms of hypothalamic dysfunction resulting in fatigue and obesity, as well as for children with presumed "common" obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.